Immediate Impact
18 standout
Citing Papers
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
2025 Standout
Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index
2024 Standout
Works of Di̇lek Erdem being referenced
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
2019
Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Di̇lek Erdem | 116 | 85 | 40 | 42 | 37 | 253 | |
| Laura Mazilu | 64 | 70 | 59 | 28 | 45 | 294 | |
| Amanda R. Kahl | 154 | 75 | 37 | 17 | 33 | 263 | |
| Chaoyi Zheng | 118 | 84 | 59 | 55 | 21 | 335 | |
| Delia Cortés‐Guiral | 127 | 184 | 65 | 14 | 27 | 332 | |
| Annie Hung | 121 | 63 | 30 | 13 | 30 | 313 | |
| Khalid Matin | 125 | 81 | 52 | 47 | 29 | 334 | |
| Michael Richardson | 73 | 35 | 50 | 15 | 33 | 280 | |
| Marie Lauzon | 74 | 45 | 33 | 24 | 34 | 260 | |
| Darren S. Bryan | 87 | 105 | 100 | 20 | 29 | 290 | |
| Kimberly A. Herget | 124 | 31 | 53 | 24 | 23 | 280 |
All Works
Login with ORCID to disown or claim papers
Loading papers...